drugset / Trial / NCT01295931
Nuclear and Near-Infrared (NIR) Imaging in Melanoma
Phase 1
Completed
20 enrolled
M.D. Anderson Cancer Center
National Cancer Institute (NCI) · collabUniversity of Texas · collab
NaSingle-groupOpen-labelDiagnostic
Summary
Objectives: 1. To determine the feasibility of using microdose amounts of near-infrared (NIR) fluorescent contrast agent to image tumor-draining and contralateral lymphatics in melanoma patients prior to standard-of-care sentinel lymph node biopsy OR completion lymph node dissection (axillary or inguinofemoral) 2. To determine the feasibility of using nonradioactive optical imaging techniques with indocyanine green (ICG) as a fluorescent contrast agent to characterize lymphatic architecture and function by correlating the observed lymphatic structure and function with tumor and nodal status as determined from standard-of-care immunohistochemical evaluation.
Timeline
- Start
- 2011-02
- Primary completion
- 2014-10
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Indocyanine Green | Diagnostic / imaging agent | 25 ug | Other |
| Subject | Indocyanine Green | Diagnostic / imaging agent | 0.1 ml | Other |